NCT03303079View on ClinicalTrials.gov

Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Chronic Migraine

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

571

Participants

Timeline

Start Date

December 19, 2017

Primary Completion Date

November 30, 2019

Study Completion Date

November 30, 2019

Conditions
Migraine
Interventions
DRUG

TEV-48125

TEV-48125 will be subcutaneously administered once monthly for 3 months.

DRUG

TEV-48125 or placebo

TEV-48125 or placebo will be subcutaneously administered once monthly for 3 months.

DRUG

Placebo

Placebo will be subcutaneously administered once monthly for 3 months.

Trial Locations (1)

Unknown

Saitama Medical University Hospital, Iruma

Sponsors
All Listed Sponsors
lead

Otsuka Pharmaceutical Co., Ltd.

INDUSTRY